MedTrace Logo

CELZ-201-DDT for the Treatment of Chronic Lower Back Pain

NCT07137559 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-08-22

No results posted yet for this study

Summary

CELZ-201-DDT is an investigational (experimental) cell therapy currently being studied for people with degenerative disc disease who have chronic lower back pain.

Conditions

  • Chronic Back Pain
  • Degenerative Disc Disease Lumbar

Interventions

DRUG

CELZ-201-DDT

CELZ-201-DDT is administered via intramuscular injection. Dosing, administration, and follow-up will be determined by the treating physician in accordance with the EA authorization and medical judgment. Safety monitoring will be performed during and after treatment, and all serious adverse events will be reported to the FDA and IRB per applicable regulations.

Sponsors & Collaborators

  • Creative Medical Technology Holdings Inc

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07137559 on ClinicalTrials.gov